1
|
Communi D, Horckmans M, Boeynaems JM. P2Y 4, P2Y 6 and P2Y 11 receptors: From the early days of cloning to their function. Biochem Pharmacol 2020; 187:114347. [PMID: 33232731 DOI: 10.1016/j.bcp.2020.114347] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 11/19/2020] [Accepted: 11/19/2020] [Indexed: 02/01/2023]
Abstract
The family of P2Y nucleotide receptors is composed of eight members differentiated by their pharmacology and their coupling to specific G-proteins and transduction mechanisms. The laboratory studying these nucleotide receptors at IRIBHM institute (Free University of Brussels) has participated actively in their cloning. We used classical cloning by homology strategies relying on polymerase chain reactions with degenerate primers or on DNA libraries screening with P2Y receptors-related primers or probes, respectively. We identified and characterised four of the eight human P2Y receptors cloned so far: P2Y4, P2Y6, P2Y11 and P2Y13 receptors. These human receptors displayed specific features in terms of pharmacology such as affinity for pyrimidine nucleotides for P2Y4 and P2Y6 receptors and differential G-protein coupling. Their specific and restricted tissue distribution compared to ubiquitous P2Y1 and P2Y2 receptors led us to study their physiological role in chosen cell systems or using mice deficient for these P2Y subtypes. These studies revealed over the years that the P2Y11 receptor was able to confer tolerogenic and tumorigenic properties to human dendritic cells and that P2Y4 and P2Y6 receptors were involved in mouse heart post-natal development and cardioprotection. P2Y receptors and their identified target genes could constitute therapeutic targets to regulate cardiac hypertrophy and regeneration. The multiple roles of P2Y receptors identified in the ischemic heart and cardiac adipose tissue could have multiple innovative clinical applications and present a major interest in the field of cardiovascular diseases. P2Y receptors can induce cardioprotection by the regulation of cardiac inflammation and the modulation of the volume and composition of cardiac adipose tissue. These findings might lead to the pre-clinical validation of P2Y receptors as new targets for the treatment of myocardial ischemia.
Collapse
Affiliation(s)
- Didier Communi
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.
| | - Michael Horckmans
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium
| | | |
Collapse
|
2
|
Stefani J, Tschesnokowa O, Parrilla M, Robaye B, Boeynaems JM, Acker-Palmer A, Zimmermann H, Gampe K. Disruption of the Microglial ADP Receptor P2Y 13 Enhances Adult Hippocampal Neurogenesis. Front Cell Neurosci 2018; 12:134. [PMID: 29867367 PMCID: PMC5966569 DOI: 10.3389/fncel.2018.00134] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 04/30/2018] [Indexed: 12/20/2022] Open
Abstract
In mammalian species, including humans, the hippocampal dentate gyrus (DG) is a primary region of adult neurogenesis. Aberrant adult hippocampal neurogenesis is associated with neurological pathologies. Understanding the cellular mechanisms controlling adult hippocampal neurogenesis is expected to open new therapeutic strategies for mental disorders. Microglia is intimately associated with neural progenitor cells in the hippocampal DG and has been implicated, under varying experimental conditions, in the control of the proliferation, differentiation and survival of neural precursor cells. But the underlying mechanisms remain poorly defined. Using fluorescent in situ hybridization we show that microglia in brain express the ADP-activated P2Y13 receptor under basal conditions and that P2ry13 mRNA is absent from neurons, astrocytes, and neural progenitor cells. Disrupting P2ry13 decreases structural complexity of microglia in the hippocampal subgranular zone (SGZ). But it increases progenitor cell proliferation and new neuron formation. Our data suggest that P2Y13 receptor-activated microglia constitutively attenuate hippocampal neurogenesis. This identifies a signaling pathway whereby microglia, via a nucleotide-mediated mechanism, contribute to the homeostatic control of adult hippocampal neurogenesis. Selective P2Y13R antagonists could boost neurogenesis in pathological conditions associated with impaired hippocampal neurogenesis.
Collapse
Affiliation(s)
- Jennifer Stefani
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany
| | - Olga Tschesnokowa
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany
| | - Marta Parrilla
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany.,Max-Planck-Institute for Brain Research, Frankfurt am Main, Germany
| | - Bernard Robaye
- Institute of Interdisciplinary Research, School of Medicine, Université Libre de Bruxelles, Bruxelles, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, School of Medicine, Université Libre de Bruxelles, Bruxelles, Belgium
| | - Amparo Acker-Palmer
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany.,Max-Planck-Institute for Brain Research, Frankfurt am Main, Germany.,Focus Program Translational Neurosciences (FTN), University of Mainz, Mainz, Germany
| | - Herbert Zimmermann
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany
| | - Kristine Gampe
- Institute of Cell Biology and Neuroscience and Buchmann Institute for Molecular Life Sciences, Goethe-University, Frankfurt am Main, Germany
| |
Collapse
|
3
|
Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata K, Zissel G, Goldmann T, Lungarella G, Ferrari D, Di Virgilio F, Robaye B, Boeynaems JM, Blackburn MR, Idzko M. The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget 2018; 8:35962-35972. [PMID: 28415591 PMCID: PMC5482630 DOI: 10.18632/oncotarget.16414] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Accepted: 03/10/2017] [Indexed: 12/14/2022] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a devastating disease with few available treatment options. Recently, the involvement of purinergic receptor subtypes in the pathogenesis of different lung diseases has been demonstrated. Here we investigated the role of the purinergic receptor subtype P2Y2 in the context of fibrotic lung diseases.The concentration of different nucleotides was measured in the broncho-alveolar lavage (BAL) fluid derived from IPF patients and animals with bleomycin-induced pulmonary fibrosis. In addition expression of P2Y2 receptors by different cell types was determined. To investigate the functional relevance of P2Y2 receptors for the pathogenesis of the disease the bleomycin model of pulmonary fibrosis was used. Finally, experiments were performed in pursuit of the involved mechanisms.Compared to healthy individuals or vehicle treated animals, extracellular nucleotide levels in the BAL fluid were increased in patients with IPF and in mice after bleomycin administration, paralleled by a functional up-regulation of P2Y2R expression. Both bleomycin-induced inflammation and fibrosis were reduced in P2Y2R-deficient compared to wild type animals. Mechanistic studies demonstrated that recruitment of neutrophils into the lungs, proliferation and migration of lung fibroblasts as well as IL6 production are key P2Y2R mediated processes.Our results clearly demonstrate the involvement of P2Y2R subtypes in the pathogenesis of fibrotic lung diseases in humans and mice and hence support the development of selective P2Y2R antagonists for the treatment of IPF.
Collapse
Affiliation(s)
- Tobias Müller
- University Hospital Freiburg, Department of Pneumology, Germany.,University Hospital RWTH Aachen, Division of Pneumology, Germany
| | - Susanne Fay
- University Hospital Freiburg, Department of Pneumology, Germany
| | | | - Harry Karmouty-Quintana
- Department of Biochemistry and Molecular Biology, Houston Medical School, University of Texas, Houston, USA
| | - Sanja Cicko
- University Hospital Freiburg, Department of Pneumology, Germany
| | - Korcan Ayata
- University Hospital Freiburg, Department of Pneumology, Germany
| | - Gernot Zissel
- University Hospital Freiburg, Department of Pneumology, Germany
| | - Torsten Goldmann
- Research Center Borstel, Clinical and Experimental Pathology, Borstel, Germany
| | - Giuseppe Lungarella
- Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy
| | - Davide Ferrari
- Department of Experimental and Diagnostic Medicine, Section of General Pathology and Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, Italy
| | - Francesco Di Virgilio
- Department of Experimental and Diagnostic Medicine, Section of General Pathology and Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, Italy
| | - Bernard Robaye
- IRIBHM and Erasme Hospital, Université Libre de Bruxelles, Belgium
| | | | - Michael R Blackburn
- Department of Biochemistry and Molecular Biology, Houston Medical School, University of Texas, Houston, USA
| | - Marco Idzko
- University Hospital Freiburg, Department of Pneumology, Germany
| |
Collapse
|
4
|
Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata CK, Zissel G, Goldmann T, Lungarella G, Ferrari D, Di Virgilio F, Robaye B, Boeynaems JM, Lazarowski ER, Blackburn MR, Idzko M. P2Y 6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. Front Immunol 2017; 8:1028. [PMID: 28878780 PMCID: PMC5572280 DOI: 10.3389/fimmu.2017.01028] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 08/09/2017] [Indexed: 01/27/2023] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is a disease with a poor prognosis and very few available treatment options. The involvement of the purinergic receptor subtypes P2Y2 and P2X7 in fibrotic lung disease has been demonstrated recently. In this study, we investigated the role of P2Y6 receptors in the pathogenesis of IPF in humans and in the animal model of bleomycin-induced lung injury. P2Y6R expression was upregulated in lung structural cells but not in bronchoalveolar lavage (BAL) cells derived from IPF patients as well as in animals following bleomycin administration. Furthermore, BAL fluid levels of the P2Y6R agonist uridine-5′-diphosphate were elevated in animals with bleomycin-induced pulmonary fibrosis. Inflammation and fibrosis following bleomycin administration were reduced in P2Y6R-deficient compared to wild-type animals confirming the pathophysiological relevance of P2Y6R subtypes for fibrotic lung diseases. Experiments with bone marrow chimeras revealed the importance of P2Y6R expression on lung structural cells for pulmonary inflammation and fibrosis. Similar effects were obtained when animals were treated with the P2Y6R antagonist MRS2578. In vitro studies demonstrated that proliferation and secretion of the pro-inflammatory/pro-fibrotic cytokine IL-6 by lung fibroblasts are P2Y6R-mediated processes. In summary, our results clearly demonstrate the involvement of P2Y6R subtypes in the pathogenesis of pulmonary fibrosis. Thus, blocking pulmonary P2Y6 receptors might be a new target for the treatment of IPF.
Collapse
Affiliation(s)
- Tobias Müller
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany.,Division of Pneumology, University Hospital RWTH Aachen, Aachen, Germany
| | - Susanne Fay
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany
| | | | - Harry Karmouty-Quintana
- Department of Biochemistry and Molecular Biology, University of Texas, Houston, TX, United States
| | - Sanja Cicko
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany
| | - Cemil Korcan Ayata
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany
| | - Gernot Zissel
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany
| | - Torsten Goldmann
- Clinical and Experimental Pathology, Research Center Borstel, Borstel, Germany
| | - Giuseppe Lungarella
- Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy
| | - Davide Ferrari
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy
| | - Francesco Di Virgilio
- Department of Morphology, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, Ferrara, Italy
| | - Bernard Robaye
- IRIBHM and Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Eduardo R Lazarowski
- Cystic Fibrosis Research Center, Marsico Lung Institute, University of North Carolina, Chapel Hill, NC, United States
| | - Michael R Blackburn
- Department of Biochemistry and Molecular Biology, University of Texas, Houston, TX, United States
| | - Marco Idzko
- Department of Pneumology, University Medical Center Freiburg, Freiburg, Germany
| |
Collapse
|
5
|
Lemaire A, Vanorlé M, Horckmans M, di Pietrantonio L, Clouet S, Robaye B, Boeynaems JM, Communi D. Mouse P2Y 4 Nucleotide Receptor Is a Negative Regulator of Cardiac Adipose-Derived Stem Cell Differentiation and Cardiac Fat Formation. Stem Cells Dev 2016; 26:363-373. [PMID: 27855539 DOI: 10.1089/scd.2016.0166] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Cardiac adipose tissue-derived stem cells (cASCs) have the ability to differentiate into multiple cell lineages giving them a high potential for use in regenerative medicine. Cardiac fat tissue still raises many unsolved questions related to its formation and features. P2Y nucleotide receptors have already been described as regulators of differentiation of bone-marrow derived stem cells, but remain poorly investigated in cASCs. We defined, in this study, the P2Y4 nucleotide receptor as a negative regulator of cardiac fat formation and cASC adipogenic differentiation. Higher expression of P2Y4 receptor in cardiac fat tissue was observed compared to other adipose tissues. P2Y4-null mice displayed a higher mass of cardiac adipose tissue specifically. We therefore examined the role of P2Y4 receptor in cASC adipogenic differentiation. An inhibitory effect of uridine 5'-triphosphate (UTP), ligand of P2Y4, was observed on the maturation state of differentiated cASCs, and on the expression of adipogenesis-linked genes and adiponectin, a cardioprotective adipokine. Higher adiponectin secretion by P2Y4-null adipocytes could be linked with cardioprotection previously observed in the heart of P2Y4-null ischemic mice. We realized here left anterior descending artery ligation on simple and double-knockout mice for P2Y4 and adiponectin. No cardioprotective effect of P2Y4 loss was observed in the absence of adiponectin secretion. In addition, P2Y4 loss was correlated with higher expression of UCP-1 (uncoupling protein-1) and CD137, two markers of brown/beige cardiac adipocytes. Our data highlight the P2Y4 receptor as an inhibitor of cardiac fat formation and cASC adipogenic differentiation, and as a potential therapeutic target in the regulation of cardioprotective function of cardiac fat.
Collapse
Affiliation(s)
- Anne Lemaire
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| | - Marion Vanorlé
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| | - Michael Horckmans
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| | - Larissa di Pietrantonio
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| | - Sophie Clouet
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| | - Bernard Robaye
- 2 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium .,3 Department of Laboratory Medicine, Erasme Hospital, Université Libre de Bruxelles , Brussels, Belgium
| | - Didier Communi
- 1 Institute of Interdisciplinary Research (IRIBHM) , Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
6
|
Kauffenstein G, Tamareille S, Prunier F, Roy C, Ayer A, Toutain B, Billaud M, Isakson BE, Grimaud L, Loufrani L, Rousseau P, Abraham P, Procaccio V, Monyer H, de Wit C, Boeynaems JM, Robaye B, Kwak BR, Henrion D. Central Role of P2Y6 UDP Receptor in Arteriolar Myogenic Tone. Arterioscler Thromb Vasc Biol 2016; 36:1598-606. [PMID: 27255725 DOI: 10.1161/atvbaha.116.307739] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Accepted: 05/17/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Myogenic tone (MT) of resistance arteries ensures autoregulation of blood flow in organs and relies on the intrinsic property of smooth muscle to contract in response to stretch. Nucleotides released by mechanical strain on cells are responsible for pleiotropic vascular effects, including vasoconstriction. Here, we evaluated the contribution of extracellular nucleotides to MT. APPROACH AND RESULTS We measured MT and the associated pathway in mouse mesenteric resistance arteries using arteriography for small arteries and molecular biology. Of the P2 receptors in mouse mesenteric resistance arteries, mRNA expression of P2X1 and P2Y6 was dominant. P2Y6 fully sustained UDP/UTP-induced contraction (abrogated in P2ry6(-/-) arteries). Preventing nucleotide hydrolysis with the ectonucleotidase inhibitor ARL67156 enhanced pressure-induced MT by 20%, whereas P2Y6 receptor blockade blunted MT in mouse mesenteric resistance arteries and human subcutaneous arteries. Despite normal hemodynamic parameters, P2ry6(-/-) mice were protected against MT elevation in myocardial infarction-induced heart failure. Although both P2Y6 and P2Y2 receptors contributed to calcium mobilization, P2Y6 activation was mandatory for RhoA-GTP binding, myosin light chain, P42-P44, and c-Jun N-terminal kinase phosphorylation in arterial smooth muscle cells. In accordance with the opening of a nucleotide conduit in pressurized arteries, MT was altered by hemichannel pharmacological inhibitors and impaired in Cx43(+/-) and P2rx7(-/-) mesenteric resistance arteries. CONCLUSIONS Signaling through P2 nucleotide receptors contributes to MT. This mechanism encompasses the release of nucleotides coupled to specific autocrine/paracrine activation of the uracil nucleotide P2Y6 receptor and may contribute to impaired tissue perfusion in cardiovascular diseases.
Collapse
Affiliation(s)
- Gilles Kauffenstein
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.).
| | - Sophie Tamareille
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Fabrice Prunier
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Charlotte Roy
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Audrey Ayer
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Bertrand Toutain
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Marie Billaud
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Brant E Isakson
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Linda Grimaud
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Laurent Loufrani
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Pascal Rousseau
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Pierre Abraham
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Vincent Procaccio
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Hannah Monyer
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Cor de Wit
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Jean-Marie Boeynaems
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Bernard Robaye
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Brenda R Kwak
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| | - Daniel Henrion
- From the MITOVASC Institute, CNRS UMR 6214, INSERM U1083 (G.K., C.R., A.A., B.T., L.G., L.L., P.A., V.P., D.H.) and EA 3860 Cardioprotection Remodelage et Thrombose, University of Angers, Angers, France (S.T., F.P.); Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville (M.B., B.E.I.); University Hospital Angers, Angers, France (G.K., P.R., P.A., V.P.); Department of Clinical Neurobiology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany (H.M.); Institut für Physiologie, Universität zu Lübeck and Deutsches Zentrum für Herz-Kreislauf-Forschung, Lübeck, Germany (C.d.W.); Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium (J.-M.B., B.R.); and Departments of Pathology and Immunology and Medical Specializations - Cardiology, University of Geneva, Geneva, Switzerland (B.R.K.)
| |
Collapse
|
7
|
Clouet S, Di Pietrantonio L, Daskalopoulos EP, Esfahani H, Horckmans M, Vanorlé M, Lemaire A, Balligand JL, Beauloye C, Boeynaems JM, Communi D. Loss of Mouse P2Y6 Nucleotide Receptor Is Associated with Physiological Macrocardia and Amplified Pathological Cardiac Hypertrophy. J Biol Chem 2016; 291:15841-52. [PMID: 27231349 DOI: 10.1074/jbc.m115.684118] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Indexed: 12/13/2022] Open
Abstract
The study of the mechanisms leading to cardiac hypertrophy is essential to better understand cardiac development and regeneration. Pathological conditions such as ischemia or pressure overload can induce a release of extracellular nucleotides within the heart. We recently investigated the potential role of nucleotide P2Y receptors in cardiac development. We showed that adult P2Y4-null mice displayed microcardia resulting from defective cardiac angiogenesis. Here we show that loss of another P2Y subtype called P2Y6, a UDP receptor, was associated with a macrocardia phenotype and amplified pathological cardiac hypertrophy. Cardiomyocyte proliferation and size were increased in vivo in hearts of P2Y6-null neonates, resulting in enhanced postnatal heart growth. We then observed that loss of P2Y6 receptor enhanced pathological cardiac hypertrophy induced after isoproterenol injection. We identified an inhibitory effect of UDP on in vitro isoproterenol-induced cardiomyocyte hyperplasia and hypertrophy. The present study identifies mouse P2Y6 receptor as a regulator of cardiac development and cardiomyocyte function. P2Y6 receptor could constitute a therapeutic target to regulate cardiac hypertrophy.
Collapse
Affiliation(s)
- Sophie Clouet
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels
| | - Larissa Di Pietrantonio
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels
| | | | - Hrag Esfahani
- the Unit of Pharmacology and Therapeutics, Université Catholique de Louvain, UCL-FATH 5349, 1200 Brussels, and
| | - Michael Horckmans
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels
| | - Marion Vanorlé
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels
| | - Anne Lemaire
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels
| | - Jean-Luc Balligand
- the Unit of Pharmacology and Therapeutics, Université Catholique de Louvain, UCL-FATH 5349, 1200 Brussels, and
| | - Christophe Beauloye
- the Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, 1200 Brussels
| | - Jean-Marie Boeynaems
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels, the Department of Laboratory Medicine, Erasme Hospital, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Didier Communi
- From the Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, 1070 Brussels,
| |
Collapse
|
8
|
Nishimura A, Sunggip C, Tozaki-Saitoh H, Shimauchi T, Numaga-Tomita T, Hirano K, Ide T, Boeynaems JM, Kurose H, Tsuda M, Robaye B, Inoue K, Nishida M. Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II–induced hypertension. Sci Signal 2016; 9:ra7. [DOI: 10.1126/scisignal.aac9187] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The angiotensin (Ang) type 1 receptor (AT1R) promotes functional and structural integrity of the arterial wall to contribute to vascular homeostasis, but this receptor also promotes hypertension. In our investigation of how Ang II signals are converted by the AT1R from physiological to pathological outputs, we found that the purinergic P2Y6 receptor (P2Y6R), an inflammation-inducible G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptor (GPCR), promoted Ang II–induced hypertension in mice. In mice, deletion of P2Y6R attenuated Ang II–induced increase in blood pressure, vascular remodeling, oxidative stress, and endothelial dysfunction. AT1R and P2Y6R formed stable heterodimers, which enhanced G protein–dependent vascular hypertrophy but reduced β-arrestin–dependent AT1R internalization. Pharmacological disruption of AT1R-P2Y6R heterodimers by the P2Y6R antagonist MRS2578 suppressed Ang II–induced hypertension in mice. Furthermore, P2Y6R abundance increased with age in vascular smooth muscle cells. The increased abundance of P2Y6R converted AT1R-stimulated signaling in vascular smooth muscle cells from β-arrestin–dependent proliferation to G protein–dependent hypertrophy. These results suggest that increased formation of AT1R-P2Y6R heterodimers with age may increase the likelihood of hypertension induced by Ang II.
Collapse
|
9
|
Kauffenstein G, Roy C, Grimaud L, Toutain B, Boeynaems JM, Robaye B, Henrion D. 0343 : Essential role of P2Y6 UDP receptor in Angiotensin-II dependent arterial hypertension. Archives of Cardiovascular Diseases Supplements 2015. [DOI: 10.1016/s1878-6480(15)30154-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
10
|
Lichtenstein L, Serhan N, Espinosa-Delgado S, Fabre A, Annema W, Tietge UJF, Robaye B, Boeynaems JM, Laffargue M, Perret B, Martinez LO. Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport. Cardiovasc Res 2015; 106:314-23. [PMID: 25770145 DOI: 10.1093/cvr/cvv109] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 03/07/2015] [Indexed: 11/14/2022] Open
Abstract
AIMS High-density lipoproteins (HDLs) protect against atherosclerosis mainly due to their function in hepatobiliary reverse cholesterol transport (RCT). This is a process whereby excess cholesterol from peripheral tissues is transported by HDL particles to the liver for further metabolism and biliary excretion. Hepatic uptake of HDL holoparticles involves the P2Y13 receptor, independently of the selective cholesteryl ester uptake mediated by scavenger receptor class B, type I (SR-BI). Accordingly, P2Y13-deficient mice (P2Y13 (-/-)) have impaired RCT. This study assessed whether P2Y13 deficiency would affect atherosclerotic development. METHODS AND RESULTS P2Y13 (-/-) mice were crossbred with atherosclerosis-prone apoE(-/-) mice. When 15 weeks old, P2Y13 (-/-)/apoE(-/-) mice had more aortic sinus lesions than apoE(-/-) mice. Bone marrow transplantation showed that the absence of the P2Y13 receptor in blood cells did not lead to significantly greater atherosclerotic plaque size formation compared with control apoE(-/-) reconstituted animals. Conversely, the absence of the P2Y13 receptor, except in blood cells, resulted in lesion sizes similar to that in P2Y13 (-/-)/apoE(-/-) reconstituted mice, pointing to a role for non-haematopoietic-derived P2Y13. Unexpectedly, P2Y13 (-/-)/apoE(-/-) mice displayed a lower HDL-cholesterol level than apoE(-/-) mice, which might be due to greater SR-BI expression in the liver. However, P2Y13 deficiency in apoE(-/-) mice was translated into reduced biliary and faecal sterol excretion and impaired RCT from macrophage to faeces, suggesting that an alteration in hepatobiliary RCT could be solely responsible for the greater atherosclerosis observed. CONCLUSION The P2Y13 receptor protects against atherosclerosis, primarily through its role in hepatobiliary RCT.
Collapse
Affiliation(s)
- Laeticia Lichtenstein
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Nizar Serhan
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Sara Espinosa-Delgado
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Aurélie Fabre
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Wijtske Annema
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Uwe J F Tietge
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Muriel Laffargue
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Bertrand Perret
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - Laurent O Martinez
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France CHU de Toulouse, Hôpital Purpan, Toulouse, France INSERM U1048, Bât. L3, Hôpital Rangueil, BP 84225, 31432 Toulouse cedex 04, France
| |
Collapse
|
11
|
Relvas LJM, Makhoul M, Dewispelaere R, Caspers L, Communi D, Boeynaems JM, Robaye B, Bruyns C, Willermain F. P2Y2R deficiency attenuates experimental autoimmune uveitis development. PLoS One 2015; 10:e0116518. [PMID: 25692550 PMCID: PMC4334221 DOI: 10.1371/journal.pone.0116518] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 12/10/2014] [Indexed: 12/20/2022] Open
Abstract
We aimed to study the role of the nucleotide receptor P2Y2R in the development of experimental autoimmune uveitis (EAU). EAU was induced in P2Y2+/+ and P2Y2-/- mice by immunization with IRBP peptide or by adoptive transfer of in vitro restimulated semi-purified IRBP-specific enriched T lymphocytes from spleens and lymph nodes isolated from native C57Bl/6 or P2Y2+/+ and P2Y2-/- immunized mice. Clinical and histological scores were used to grade disease severity. Splenocytes and lymph node cell phenotypes were analyzed using flow cytometry. Semi-purified lymphocytes and MACS-purified CD4+ T lymphocytes from P2Y2+/+ and P2Y2-/- immunized mice were tested for proliferation and cytokine secretion. Our data show that clinical and histological scores were significantly decreased in IRBP-immunized P2Y2-/- mice as in P2Y2-/- mice adoptively transfered with enriched T lymphocytes from C57Bl/6 IRBP-immunized mice. In parallel, naïve C57Bl/6 mice adoptively transferred with T lymphocytes from P2Y2-/- IRBP-immunized mice also showed significantly less disease. No differences in term of spleen and lymph node cell recruitment or phenotype appeared between P2Y2-/- and P2Y2+/+ immunized mice. However, once restimulated in vitro with IRBP, P2Y2-/- T cells proliferate less and secrete less cytokines than the P2Y2+/+ one. We further found that antigen-presenting cells of P2Y2-/- immunized mice were responsible for this proliferation defect. Together our data show that P2Y2-/- mice are less susceptible to mount an autoimmune response against IRBP. Those results are in accordance with the danger model, which makes a link between autoreactive lymphocyte activation, cell migration and the release of danger signals such as extracellular nucleotides.
Collapse
Affiliation(s)
- Lia Judice M. Relvas
- Dpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
- * E-mail:
| | - Maya Makhoul
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Remi Dewispelaere
- Dpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Laure Caspers
- Dpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Didier Communi
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-Marie Boeynaems
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Dpt of Laboratory Medicine, Erasme Hospital, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Bernard Robaye
- The Institute of Interdisciplinary Research, IRIBHM, Gosselies, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - Catherine Bruyns
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| | - François Willermain
- Dpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium
- The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium
- Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
12
|
Horckmans M, Esfahani H, Beauloye C, Clouet S, di Pietrantonio L, Robaye B, Balligand JL, Boeynaems JM, Dessy C, Communi D. Loss of mouse P2Y4 nucleotide receptor protects against myocardial infarction through endothelin-1 downregulation. J Immunol 2015; 194:1874-81. [PMID: 25595790 DOI: 10.4049/jimmunol.1401364] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Nucleotides are released in the heart under pathological conditions, but little is known about their contribution to cardiac inflammation. The present study defines the P2Y4 nucleotide receptor, expressed on cardiac microvascular endothelial cells and involved in postnatal heart development, as an important regulator of the inflammatory response to cardiac ischemia. P2Y4-null mice displayed smaller infarcts in the left descending artery ligation model, as well as reduced neutrophil infiltration and fibrosis. Gene profiling identified inter alia endothelin-1 (ET-1) as one of the target genes of P2Y4 in ischemic heart. The reduced level of ET-1 was correlated with reduction of microvascular hyperpermeability, neutrophil infiltration, and endothelial adhesion molecule expression, and it could be explained by the decreased number of endothelial cells in P2Y4-null mice. Expression analysis of metalloproteinases and their tissue inhibitors in ischemic heart revealed reduced expression of matrix metalloproteinase (MMP)-9, reported to be potentially regulated by ET-1, and MMP-8, considered as neutrophil collagenase, as well as reduction of tissue inhibitor of MMP-1 and tissue inhibitor of MMP-4 in P2Y4-null mice. Reduction of cardiac permeability and neutrophil infiltration was also observed in P2Y4-null mice in LPS-induced inflammation model. Protection against infarction resulting from loss of P2Y4 brings new therapeutic perspectives for cardiac ischemia and remodeling.
Collapse
Affiliation(s)
- Michael Horckmans
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Hrag Esfahani
- Unité de Pharmacologie et de Thérapeutique, Université Catholique de Louvain, 1200 Brussels, Belgium
| | - Christophe Beauloye
- Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, 1200 Brussels, Belgium
| | - Sophie Clouet
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Larissa di Pietrantonio
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Bernard Robaye
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 6041 Gosselies, Belgium; and
| | - Jean-Luc Balligand
- Unité de Pharmacologie et de Thérapeutique, Université Catholique de Louvain, 1200 Brussels, Belgium
| | - Jean-Marie Boeynaems
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 1070 Brussels, Belgium; Département de Médecine de Laboratoire, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium
| | - Chantal Dessy
- Unité de Pharmacologie et de Thérapeutique, Université Catholique de Louvain, 1200 Brussels, Belgium
| | - Didier Communi
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, 1070 Brussels, Belgium;
| |
Collapse
|
13
|
Biver G, Wang N, Gartland A, Orriss I, Arnett TR, Boeynaems JM, Robaye B. Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Stem Cells 2015; 31:2747-58. [PMID: 23629754 DOI: 10.1002/stem.1411] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 03/07/2013] [Accepted: 03/26/2013] [Indexed: 12/16/2022]
Abstract
Accumulating evidence indicates that extracellular nucleotides, signaling through purinergic receptors, play a significant role in bone remodeling. Mesenchymal stem cells (MSCs) express functional P2Y receptors whose expression level is regulated during osteoblast or adipocyte differentiation. P2Y13 -deficient mice were previously shown to exhibit a decreased bone turnover associated with a reduction in the number of both osteoblasts and osteoclasts on the bone surfaces. We therefore examined whether P2Y13 R activation was involved in the osteogenic differentiation of MSC. Our study demonstrated that ADP stimulation of P2Y13 R(+/+) (but not P2Y13 R(-/-) ) adherent bone marrow stromal cells (BMSCs) increased significantly the formation of alkaline phosphatase-colony-forming units (CFU-ALP) as well as the expression of osteoblastic markers (osterix, alkaline phosphatase, and collagen I) involved in the maturation of preosteoblasts into osteoblasts. The number of CFU-ALP obtained from P2Y13 R(-/-) BMSC and the level of osteoblastic gene expression after osteogenic stimulation were strongly reduced compared to those obtained in wild-type cell cultures. In contrast, when P2Y13 R(-/-) BMSCs were incubated in an adipogenic medium, the number of adipocytes generated and the level of adipogenic gene expression (PPARγ2 and Adipsin) were higher than those obtained in P2Y13 R(+/+) MSC. Interestingly, we observed a significant increase of the number of bone marrow adipocytes in tibia of P2Y13 R(-/-) mice. In conclusion, our findings indicate that the P2Y13 R plays an important role in the balance of osteoblast and adipocyte terminal differentiation of bone marrow progenitors. Therefore, the P2Y13 receptor can be considered as a new pharmacological target for the treatment of bone diseases like osteoporosis. STEM Cells 2013;31:2747-2758.
Collapse
Affiliation(s)
- Galadrielle Biver
- Institute of Interdisciplinary Research, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Gosselies, Belgium
| | | | | | | | | | | | | |
Collapse
|
14
|
Balasubramanian R, Robaye B, Boeynaems JM, Jacobson KA. Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 receptor agonists. PLoS One 2014; 9:e116203. [PMID: 25549240 PMCID: PMC4280206 DOI: 10.1371/journal.pone.0116203] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 12/03/2014] [Indexed: 01/04/2023] Open
Abstract
Glucose uptake by peripheral tissues such as skeletal muscles and adipocytes is important in the maintenance of glucose homeostasis. We previously demonstrated that P2Y6 receptor (P2Y6R) agonists protect pancreatic islet cells from apoptosis and stimulate glucose-dependent insulin release. Here, we investigated the effects of P2Y6R activation on glucose uptake in insulin target tissues. An agonist of the P2Y6R, P1-(5′-uridine)-P3-(5′-N4-methoxycytidine)-triphosphate (MRS2957), significantly increased the uptake of [3H]2-deoxyglucose in mouse C2C12 myotubes and 3T3-L1 adipocytes, and this stimulation was significantly decreased by a selective P2Y6R antagonist N,N″-1,4-butanediyl-bis[N′-(3-isothiocyanatophenyl)thiourea] (MRS2578). Pre-incubation with Compound C (an inhibitor of 5′-AMP-activated protein kinase, AMPK), or AMPK siRNA abolished the stimulatory effect of MRS2957 on glucose uptake. Also, MRS2957 (60 min incubation) increased recruitment of the facilitated glucose transporter-4 (GLUT4) to the cell membrane, which was blocked by MRS2578. Treatment of C2C12 myotubes with MRS2957 induced significant phosphorylation of AMPK, which increase GLUT4 expression through histone deacetylase (HDAC)5 signaling. Glucose uptake in primary mouse adipocytes from wild-type mice was stimulated upon P2Y6R activation by either MRS2957 or native agonist UDP, and the P2Y6R effect was antagonized by MRS2578. However, in adipocytes from P2Y6R-knockout mice P2Y6R agonists had no effect on glucose uptake, and there was no change in the glucose uptake by insulin. Our results indicate that the P2Y6R promotes glucose metabolism in peripheral tissues, which may be mediated through AMPK signaling.
Collapse
Affiliation(s)
- Ramachandran Balasubramanian
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | | | - Kenneth A. Jacobson
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
- * E-mail:
| |
Collapse
|
15
|
Abstract
This review article provides a historical perspective on the role of purinergic signalling in the regulation of various subsets of immune cells from early discoveries to current understanding. It is now recognised that adenosine 5'-triphosphate (ATP) and other nucleotides are released from cells following stress or injury. They can act on virtually all subsets of immune cells through a spectrum of P2X ligand-gated ion channels and G protein-coupled P2Y receptors. Furthermore, ATP is rapidly degraded into adenosine by ectonucleotidases such as CD39 and CD73, and adenosine exerts additional regulatory effects through its own receptors. The resulting effect ranges from stimulation to tolerance depending on the amount and time courses of nucleotides released, and the balance between ATP and adenosine. This review identifies the various receptors involved in the different subsets of immune cells and their effects on the function of these cells.
Collapse
Affiliation(s)
- Geoffrey Burnstock
- Autonomic Neuroscience Centre, University College Medical School, Rowland Hill Street, London, NW3 2PF, UK,
| | | |
Collapse
|
16
|
Voss U, Turesson MF, Robaye B, Boeynaems JM, Olde B, Erlinge D, Ekblad E. The enteric nervous system of P2Y13 receptor null mice is resistant against high-fat-diet- and palmitic-acid-induced neuronal loss. Purinergic Signal 2014; 10:455-64. [PMID: 24510452 DOI: 10.1007/s11302-014-9408-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2013] [Accepted: 01/21/2014] [Indexed: 12/20/2022] Open
Abstract
Gastrointestinal symptoms have a major impact on the quality of life and are becoming more prevalent in the western population. The enteric nervous system (ENS) is pivotal in regulating gastrointestinal functions. Purinergic neurotransmission conveys a range of short and long-term cellular effects. This study investigated the role of the ADP-sensitive P2Y13 receptor in lipid-induced enteric neuropathy. Littermate P2Y13 (+/+) and P2Y13 (-/-) mice were fed with either a normal diet (ND) or high-fat diet (HFD) for 6 months. The intestines were analysed for morphological changes as well as neuronal numbers and relative numbers of vasoactive intestinal peptide (VIP)- and neuronal nitric oxide synthase (nNOS)-containing neurons. Primary cultures of myenteric neurons from the small intestine of P2Y13 (+/+) or P2Y13 (-/-) mice were exposed to palmitic acid (PA), the P2Y13 receptor agonist 2meSADP and the antagonist MRS2211. Neuronal survival and relative number of VIP-containing neurons were analysed. In P2Y13 (+/+), but not in P2Y13 (-/-) mice, HFD caused a significant loss of myenteric neurons in both ileum and colon. In colon, the relative numbers of VIP-containing submucous neurons were significantly lower in the P2Y13 (-/-) mice compared with P2Y13 (+/+) mice. The relative numbers of nNOS-containing submucous colonic neurons increased in P2Y13 (+/+) HFD mice. HFD also caused ileal mucosal thinning in P2Y13 (+/+) and P2Y13 (-/-) mice, compared to ND fed mice. In vitro PA exposure caused loss of myenteric neurons from P2Y13 (+/+) mice while neurons from P2Y13 (-/-) mice were unaffected. Presence of MRS2211 prevented PA-induced neuronal loss in cultures from P2Y13 (+/+) mice. 2meSADP caused no change in survival of cultured neurons. P2Y13 receptor activation is of crucial importance in mediating the HFD- and PA-induced myenteric neuronal loss in mice. In addition, the results indicate a constitutive activation of enteric neuronal apoptosis by way of P2Y13 receptor stimulation.
Collapse
Affiliation(s)
- Ulrikke Voss
- Department of Experimental Medical Science, Lund University, Sölvegatan 19, Lund, BMC B11, SE-22184, Sweden,
| | | | | | | | | | | | | |
Collapse
|
17
|
Wang N, Robaye B, Gossiel F, Boeynaems JM, Gartland A. The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development. FASEB J 2014; 28:2249-59. [PMID: 24487286 DOI: 10.1096/fj.13-243626] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Purinergic signaling mediates many cellular processes, including embryonic development and regulation of endocrine signaling. The ADP P2Y13 receptor is known to regulate bone and stem cells activities, although relatively little is known about its role in bone development. In this study we demonstrate, using contemporary techniques, that deletion of the P2Y13 receptor results in an age-dependent skeletal phenotype that is governed by changes in phosphate metabolism and hormone levels. Neonatal and postnatal (2 wk) P2Y13 receptor-knockout (KO) mice were indistinguishable from their wild-type (WT) littermate controls. A clear bone phenotype was observed in young (4-wk-old) KO mice compared WT controls, with 14% more trabecular bone, 35% more osteoblasts, 73% fewer osteoclasts, and a 17% thicker growth plate. Mature (>10 wk of age) KO mice showed the opposite bone phenotype, with 14% less trabecular bone, 22% fewer osteoblasts, and 10% thinner growth plate. This age-dependent phenotype correlated with serum fibroblast growth factor-23 (FGF-23) and phosphorus levels that were 65 and 16% higher, respectively, in young KO mice but remained unchanged in mature mice. These findings provide novel insights for the role of the P2Y13 receptor in skeletal development via coordination with hormonal regulators of phosphate homeostasis.
Collapse
Affiliation(s)
- Ning Wang
- 1The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Beech Hill Rd., Sheffield, S10 2RX, UK.
| | | | | | | | | |
Collapse
|
18
|
Lichtenstein L, Serhan N, Annema W, Combes G, Robaye B, Boeynaems JM, Perret B, Tietge UJF, Laffargue M, Martinez LO. Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport. Nutr Metab (Lond) 2013; 10:67. [PMID: 24476490 PMCID: PMC4029266 DOI: 10.1186/1743-7075-10-67] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 10/30/2013] [Indexed: 01/11/2023] Open
Abstract
Background The protective effect of HDL is mostly attributed to their metabolic function in reverse cholesterol transport (RCT), a process whereby excess cellular cholesterol is taken up from peripheral cells, processed in HDL particles, and later delivered to the liver for further metabolism and biliary secretion. Mechanistically, the purinergic P2Y13 ADP-receptor is involved in hepatic HDL endocytosis (i.e., uptake of both HDL protein + lipid moieties), which is considered an important step of RCT. Accordingly, chow-fed P2Y13 knockout (P2Y13-/-) mice exhibit lower hepatic HDL uptake, which translates into a decrease of hepatic free cholesterol content and biliary cholesterol and phospholipid secretion. Findings The aim of this study was to determine the effect of high cholesterol diet (HCD) in P2Y13-/- mice, in order to mimic high dietary cholesterol intake, which is a major cause of dyslipidemia in humans. As previously reported with chow-diet, HCD did not affect plasma lipid levels in P2Y13-/- compared with control mice but decreased hepatic free and esterified cholesterol content (p < 0.05, P2Y13-/- versus control). Interestingly, biliary lipid secretion and macrophages-to-feces RCT were more dramatically impaired in P2Y13-/- mice fed a HCD than chow-diet. HCD did not enhance atherosclerosis in P2Y13-/- compared with control mice. Conclusion This study demonstrates that high dietary cholesterol intake accentuated the metabolic phenotype of P2Y13-/- mice, with impaired hepatobiliary RCT. Although other animal models might be required to further evaluate the role of P2Y13 receptor in atherosclerosis, P2Y13 appears a promising target for therapeutic intervention aiming to stimulate RCT, particularly in individuals with lipid-rich diet.
Collapse
Affiliation(s)
- Laeticia Lichtenstein
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Nizar Serhan
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Wijtske Annema
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Guillaume Combes
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Bertrand Perret
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - Uwe J F Tietge
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Muriel Laffargue
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Laurent O Martinez
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| |
Collapse
|
19
|
Boeynaems JM, Canivet C, Chan A, Clarke MJ, Cornu C, Daemen E, Demotes J, Nys KD, Hirst B, Hundt F, Kassai B, Kerpel-Fronius S, Kiessig L, Klech H, Kraehenbuhl JP, Lafolie P, Lucht M, Niese D, Pauli-Magnus C, Peters B, Schaltenbrand R, Stockis A, Stykova M, Verheus N, Klingmann I. A European approach to clinical investigator training. Front Pharmacol 2013; 4:112. [PMID: 24058345 PMCID: PMC3766792 DOI: 10.3389/fphar.2013.00112] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2013] [Accepted: 07/19/2013] [Indexed: 12/03/2022] Open
Abstract
A better education and training of clinical investigators and their teams is one of the factors that could foster the development of clinical research in Europe, a key objective of the Innovative Medicines Initiative (IMI). PharmaTrain (an IMI programme on training in medicines development), and European Clinical Research Infrastructures Network (ECRIN) have joined forces to address this issue. An advisory group composed of representatives of universities, pharmaceutical companies and other organisations met four times between June 2011 and July 2012. This resulted in a position paper proposing a strategy to improve and harmonize clinical investigator training in Europe, and including a detailed syllabus and list of learning outcomes. Major recommendations are the establishment of minimal and mutually recognized certification requirement for investigators throughout the EU and the creation of a European platform to provide a suitable course and examination infrastructure.
Collapse
|
20
|
Wang N, Rumney RMH, Yang L, Robaye B, Boeynaems JM, Skerry TM, Gartland A. The P2Y13 receptor regulates extracellular ATP metabolism and the osteogenic response to mechanical loading. J Bone Miner Res 2013; 28:1446-56. [PMID: 23362109 DOI: 10.1002/jbmr.1877] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2012] [Revised: 12/11/2012] [Accepted: 01/07/2013] [Indexed: 11/07/2022]
Abstract
ATP release and subsequent activation of purinergic receptors has been suggested to be one of the key transduction pathways activated by mechanical stimulation of bone. The P2Y(13) receptor, recently found to be expressed by osteoblasts, has been suggested to provide a negative feedback pathway for ATP release in different cell types. Therefore, we hypothesized that the P2Y(13) receptor may contribute to the mediation of osteogenic responses to mechanical stimulation by regulating ATP metabolism by osteoblasts. To test this hypothesis, wild-type (WT) and P2Y(13) receptor knockout (P2Y(13)R-/-) mice were subject to non-invasive axial mechanical loading of the left tibiae to induce an osteogenic response. Micro-computed tomography analysis showed mechanical loading induced an osteogenic response in both strains of mice in terms of increased total bone volume and cortical bone volume, with the P2Y(13)R-/- mice having a significantly greater response. The extent of the increased osteogenic response was defined by dynamic histomorphometry data showing dramatically increased bone formation and mineral apposition rates in P2Y(13)R-/- mice compared with controls. In vitro, primary P2Y(13)R-/- osteoblasts had an accumulation of mechanically induced extracellular ATP and reduced levels of hydrolysis. In addition, P2Y(13)R-/- osteoblasts also had a reduction in their maximal alkaline phosphatase (ALP) activity, one of the main ecto-enzymes expressed by osteoblasts, which hydrolyzes extracellular ATP. In conclusion, deletion of the P2Y(13) receptor leads to an enhanced osteogenic response to mechanical loading in vivo, possibly because of the reduced extracellular ATP degradation by ALP. The augmented osteogenic response to mechanical stimulation, combined with suppressed bone remodeling activities and protection from OVX-induced bone loss after P2Y(13) receptor depletion as previously described, suggests a potential role for P2Y(13) receptor antagonist-based therapy, possibly in combination with mechanical loading, for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Ning Wang
- The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Sheffield, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
21
|
Horckmans M, Léon-Gómez E, Robaye B, Balligand JL, Boeynaems JM, Dessy C, Communi D. Gene deletion of P2Y4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise. Am J Physiol Heart Circ Physiol 2012; 303:H835-43. [PMID: 22865387 DOI: 10.1152/ajpheart.00256.2012] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Nucleotides released within the heart under pathological conditions can be involved in cardioprotection or cardiac fibrosis through the activation purinergic P2Y(2) and P2Y(6) receptors, respectively. We previously demonstrated that adult P2Y(4)-null mice display a microcardia phenotype related to a cardiac angiogenic defect. To evaluate the functional consequences of this defect, we performed here a combination of cardiac monitoring and exercise tests. We investigated the exercise capacity of P2Y(4) wild-type and P2Y(4)-null mice in forced swimming and running tests. Analysis of their stress, locomotion, and resignation was realized in open field, black and white box, and tail suspension experiments. Exercise-induced cardiac hypertrophy was evaluated after repeated and prolonged exercise in P2Y(4) wild-type and P2Y(4)-null hearts. We showed that P2Y(4)-null mice have a lower exercise capacity in both swimming and treadmill tests. This was not related to decreased motivation or increased stress, since open field, white and black box, and mouse tail suspension tests gave comparable results in P2Y(4) wild-type and P2Y(4)-null mice. Heart rate and blood pressure rose normally in P2Y(4)-null swimming mice equipped with a telemetric implant. On the contrary, we observed a delayed recovery of postexercise blood pressure after exercise in P2Y(4)-null mice. The heart rate increment in response to catecholamines was also similar in P2Y(4) wild-type and P2Y(4)-null implanted mice, which is consistent with a similar level of cardiac β-receptor expression. Interestingly, the heart of P2Y(4)-null mice displayed a reduced sympathetic innervation associated with a decreased norepinephrine level. We also demonstrated that exercise-induced cardiac hypertrophy was lower in P2Y(4)-null mice after repeated and prolonged exercise. This was associated with a lower increase in cardiomyocyte size and microvessel density. In conclusion, besides its role in cardiac development, P2Y(4) receptor could constitute an important regulator of acute and chronic response to exercise.
Collapse
Affiliation(s)
- Michael Horckmans
- Institute of Interdisciplinary Research, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
22
|
Uesugi A, Kataoka A, Tozaki-Saitoh H, Koga Y, Tsuda M, Robaye B, Boeynaems JM, Inoue K. Involvement of protein kinase D in uridine diphosphate-induced microglial macropinocytosis and phagocytosis. Glia 2012; 60:1094-105. [PMID: 22488958 DOI: 10.1002/glia.22337] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2011] [Accepted: 03/13/2012] [Indexed: 11/09/2022]
Abstract
The clearance of tissue debris by microglia is a crucial component of maintaining brain homeostasis. Microglia continuously survey the brain parenchyma and utilize extracellular nucleotides to trigger the initiation of their dynamic responses. Extracellular uridine diphosphate (UDP), which leaks or is released from damaged neurons, has been reported to stimulate the phagocytotic activity of microglia through P2Y(6) receptor activation. However, the intracellular mechanisms underlying microglial P2Y(6) receptor signals have not been identified. In this study, we demonstrated that UDP stimulation induced immediate and long-lasting dynamic movements in the cell membrane. After 60 min of UDP stimulation, there was an upregulation in the number of large vacuoles formed in the cell that incorporate extracellular fluorescent-labeled dextran, which indicates microglial macropinocytosis. In addition, UDP-induced vacuole formation and continuous membrane motility were suppressed by the protein kinase D (PKD) inhibitors, Gö6976 and CID755673, unlike Gö6983, which is far less sensitive to PKD. The inhibition of PKD also reduced UDP-induced incorporation of fluorescent-labeled dextran and soluble β-amyloid and phagocytosis of microspheres. UDP induced rapid phosphorylation and membrane translocation of PKD, which was abrogated by the inhibition of protein kinase C (PKC) with Gö6983. However, Gö6983 failed to suppress UDP-induced incorporation of microspheres. Finally, we found that inhibition of PKD by CID755673 significantly suppressed UDP-induced engulfment of IgG-opsonized microspheres. These data suggest that a PKC-independent function of PKD regulates UDP-induced membrane movement and contributes to the increased uptake of extracellular fluid and microspheres in microglia.
Collapse
Affiliation(s)
- Ayumi Uesugi
- Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi, Fukuoka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
23
|
|
24
|
Horckmans M, Robaye B, Léon-Gόmez E, Lantz N, Unger P, Dol-Gleizes F, Clouet S, Cammarata D, Schaeffer P, Savi P, Gachet C, Balligand JL, Dessy C, Boeynaems JM, Communi D. P2Y(4) nucleotide receptor: a novel actor in post-natal cardiac development. Angiogenesis 2012; 15:349-60. [PMID: 22437266 DOI: 10.1007/s10456-012-9265-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Accepted: 03/10/2012] [Indexed: 12/21/2022]
Abstract
Communication between endothelial cells and cardiomyocytes is critical for cardiac development and regeneration. However the mechanisms involved in these endothelial-cardiomyocyte interactions remain poorly understood. Nucleotides are released within the heart, especially under ischemia or pressure overload. The function of P2Y nucleotide receptors in cardiac development has never been investigated. Here we show that adult P2Y(4)-null mice display microcardia. P2Y(4) nucleotide receptor is expressed in cardiac endothelial cells but not in cardiomyocytes. Loss of P2Y(4) in cardiac endothelial cells strongly inhibits their growth, migration and PDGF-B secretion in response to UTP. Proliferation of microvessels and cardiomyocytes is reduced in P2Y(4)-null hearts early after birth, resulting in reduced heart growth. Our study uncovers mouse P2Y(4) receptor as an essential regulator of cardiac endothelial cell function, and illustrates the involvement of endothelial-cardiomyocyte interactions in post-natal heart development. We also detected P2Y(4) expression in human cardiac microvessels. P2Y(4) receptor could constitute a therapeutic target to regulate cardiac remodelling and post-ischemic revascularisation.
Collapse
Affiliation(s)
- Michael Horckmans
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Building C (5th floor), Campus Erasme, 808 Route de Lennik, 1070, Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Wang N, Robaye B, Agrawal A, Skerry TM, Boeynaems JM, Gartland A. Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. Mol Endocrinol 2011; 26:142-52. [PMID: 22108801 DOI: 10.1210/me.2011-1083] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Osteoporosis is a condition of excessive and uncoupled bone turnover, in which osteoclastic resorption exceeds osteoblastic bone formation, resulting in an overall net bone loss, bone fragility, and morbidity. Although numerous treatments have been developed to inhibit bone loss by blocking osteoclastic bone resorption, understanding of the mechanisms behind bone loss is incomplete. The purinergic signaling system is emerging to be a pivotal regulator of bone homeostasis, and extracellular ADP has previously been shown to be a powerful osteolytic agent in vitro. We report here that deletion of the P2Y(13) receptor, a G protein-coupled receptor for extracellular ADP, leads to a 40% reduction in trabecular bone mass, 50% reduction in osteoblast and osteoclast numbers in vivo, as well as activity in vitro, and an overall 50% reduction in the rate of bone remodeling in mice in vivo. Down-regulation of RhoA/ROCK I signaling and a reduced ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin observed in osteoblasts from P2Y(13)R(-/-) mice might explain this bone phenotype. Furthermore, because one of the main causes of osteoporosis in older women is lack of estrogen, we examined the effect of ovariectomy of the P2Y(13)R(-/-) mice and found them to be protected from ovariectomy-induced bone loss by up to 65%. These data confirm a role of purinergic ADP signaling in the skeleton, whereby deletion of the P2Y(13) receptor leads to reduced bone turnover rates, which provide a protective advantage in conditions of accelerated bone turnover such as oestrogen deficiency-induced osteoporosis.
Collapse
Affiliation(s)
- Ning Wang
- The Mellanby Centre for Bone Research, Department of Human Metabolism, The University of Sheffield, Sheffield S10 2RX, United Kingdom
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
Accumulating evidence indicates that extracellular nucleotides, signaling through P2 receptors, play a significant role in bone remodeling. Osteoclasts (the bone-resorbing cell) and osteoblasts (the bone-forming cell) display expression of the G protein-coupled P2Y(6) receptor, but the role of this receptor in modulating cell function is unclear. Here, we demonstrate that extracellular UDP, acting via P2Y(6) receptors, stimulates the formation of osteoclasts from precursor cells, while also enhancing the resorptive activity of mature osteoclasts. Furthermore, osteoclasts derived from P2Y(6) receptor-deficient (P2Y(6)R(-/-)) animals displayed defective function in vitro. Using dual energy x-ray absorptiometry scanning and microcomputed tomographic analysis we showed that P2Y(6)R(-/-) mice have increased bone mineral content, cortical bone volume, and cortical thickness in the long bones and spine, whereas trabecular bone parameters were unaffected. Histomorphometric analysis showed the perimeter of the bone occupied by osteoclasts on the endocortical and trabecular surfaces was decreased in P2Y(6)R(-/-) mice. Taken together these results show the P2Y(6) receptor may play an important role in the regulation of bone cell function in vivo.
Collapse
Affiliation(s)
- Isabel R Orriss
- Department of Cell and Developmental Biology, University College London, London WC1E 6BT, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
27
|
Orriss I, Syberg S, Wang N, Robaye B, Gartland A, Jorgensen N, Arnett T, Boeynaems JM. Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed) 2011; 3:1038-46. [PMID: 21622253 DOI: 10.2741/208] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The action of extracellular nucleotides is mediated by ionotropic P2X receptors and G-protein coupled P2Y receptors. The human genome contains 7 P2X and 8 P2Y receptor genes. Knockout mice strains are available for most of them. As their phenotypic analysis is progressing, bone abnormalities have been observed in an impressive number of these mice: distinct abnormalities in P2X7-/- mice, depending on the gene targeting construct and the genetic background, decreased bone mass in P2Y1-/- mice, increased bone mass in P2Y2-/- mice, decreased bone resorption in P2Y6-/- mice, decreased bone formation and bone resorption in P2Y13-/- mice. These findings demonstrate the unexpected importance of extracellular nucleotide signalling in the regulation of bone metabolism via multiple P2 receptors and distinct mechanisms involving both osteoblasts and osteoclasts.
Collapse
Affiliation(s)
- Isabel Orriss
- Department of Cell and Developmental Biology, University College London, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Vieira RP, Müller T, Grimm M, von Gernler V, Vetter B, Dürk T, Cicko S, Ayata CK, Sorichter S, Robaye B, Zeiser R, Ferrari D, Kirschbaum A, Zissel G, Virchow JC, Boeynaems JM, Idzko M. Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. Am J Respir Crit Care Med 2011; 184:215-23. [PMID: 21512170 DOI: 10.1164/rccm.201011-1762oc] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
RATIONALE Extracellular nucleotides have recently been identified as proinflammatory mediators involved in asthma pathogenesis by signaling via purinergic receptors, but the role of the purinergic receptor type 6 (P2Y6R) has not been previously investigated. OBJECTIVES To investigate the role of P2Y6R in asthma pathogenesis. METHODS Acute and chronic OVA model and also HDM model of allergic inflammation in C57Bl/6 mice treated with specific P2Y6R antagonist and P2Y6R(-/-) mice were evaluated for classical features of asthmatic inflammation. In addition, primary epithelial cell culture from human and epithelial cell lines from mouse and human were stimulated with P2Y6R agonist and treated with P2Y6R antagonist and assessed for IL-6, IL-8/CXCL8 and KC levels. Experiments with P2Y6R(-/-) and P2Y6R(+/+) chimera were performed to discriminate the role of P2Y6R activation in structural lung cells and in cells from hematopoietic system. MEASUREMENTS AND MAIN RESULTS We observed that the intratracheal application of a P2Y6R antagonist (MRS2578) and P2Y6R deficiency inhibited cardinal features of asthma, such as bronchoalveolar lavage eosinophilia, airway remodeling, Th2 cytokine production, and bronchial hyperresponsiveness in the ovalbumin-alum model. MRS2578 was also effective in reducing airway inflammation in a model using house dust mite extracts to induce allergic lung inflammation. Experiments with bone marrow chimeras revealed the importance of the P2Y6R expression on lung structural cells in airway inflammation. In accordance with this finding, we found a strong up-regulation of P2Y6 expression on airway epithelial cells of animals with experimental asthma. Concerning the underlying mechanism, we observed that MRS2578 inhibited the release of IL-6 and IL-8/KC by lung epithelial cells in vivo, whereas intrapulmonary application of the P2Y6R agonist uridine-5'-diphosphate increased the bronchoalveolar levels of IL-6 and KC. In addition, selective activation of P2Y6 receptors induced the release of IL-6 and KC/IL-8 by murine and human lung epithelial cells in vitro. CONCLUSIONS P2Y6R expression on airway epithelial cells is up-regulated during acute and chronic allergic airway inflammation, and selective blocking of P2Y6R or P2Y6R deficiency on the structural cells reduces cardinal features of experimental asthma. Thus, blocking pulmonary P2Y6R might be a target for the treatment of allergic airway inflammation.
Collapse
|
29
|
Jørgensen NR, Boeynaems JM, Di Virgilio F. European meeting "P2 receptors: new targets for the treatment of osteoporosis". Purinergic Signal 2011; 7:275-6. [PMID: 21484088 DOI: 10.1007/s11302-011-9223-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2011] [Accepted: 02/02/2011] [Indexed: 11/25/2022] Open
Affiliation(s)
- Niklas Rye Jørgensen
- Research Center of Aging and Osteoporosis, Department of Medicine and Department of Clinical Biochemistry, Copenhagen University Hospital Glostrup, Glostrup, Denmark
| | | | | |
Collapse
|
30
|
Boeynaems JM, Sirtori CR. The unexpected roles of extracellular ADP and P2Y(13) receptor in reverse cholesterol transport. Purinergic Signal 2010; 6:361-3. [PMID: 21437006 DOI: 10.1007/s11302-010-9211-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Accepted: 12/07/2010] [Indexed: 10/18/2022] Open
|
31
|
Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol 2010; 185:5900-6. [PMID: 20952684 DOI: 10.4049/jimmunol.0901799] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The effects of ADP on the biology of dendritic cells have been studied much less than those of ATP or adenosine. In this study, we showed that adenosine-5'-O-(2-thiodiphosphate) (ADPβS) induced intracellular Ca(2+) transients in murine dendritic cells (DCs). This effect was abolished by AR-C69931MX, a dual P2Y(12) and P2Y(13) receptor antagonist. RT-PCR experiments revealed the expression of both P2Y(12) and P2Y(13) mRNA in DCs. The Ca(2+) response to ADPβS was maintained in P2Y(13)-deficient DCs, whereas it was abolished completely in P2Y(12)(-/-) DCs. ADPβS stimulated FITC-dextran and OVA capture in murine DCs through macropinocytosis, and this effect was abolished in P2Y(12)(-/-) DCs. ADPβS had a similar effect on FITC-dextran uptake by human monocyte-derived DCs. OVA loading in the presence of ADPβS increased the capacity of DCs to stimulate OVA-specific T cells, whereas ADPβS had no effect on the ability of DCs to stimulate allogeneic T cells. Moreover, after immunization against OVA, the serum level of anti-OVA IgG1 was significantly lower in P2Y(12)(-/-) mice than that in wild-type controls. In conclusion, we have shown that the P2Y(12) receptor is expressed in murine DCs and that its activation increased Ag endocytosis by DCs with subsequent enhancement of specific T cell activation.
Collapse
Affiliation(s)
- Abduelhakem Ben Addi
- Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Gosselies, Belgium
| | | | | | | | | |
Collapse
|
32
|
Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T, Briand F, Collet X, Nijstad N, Tietge UJF, Robaye B, Perret B, Boeynaems JM, Martinez LO. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010; 52:1477-83. [PMID: 20830789 DOI: 10.1002/hep.23897] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
UNLABELLED A major atheroprotective functionality of high-density lipoproteins (HDLs) is to promote "reverse cholesterol transport" (RCT). In this process, HDLs mediate the efflux and transport of cholesterol from peripheral cells and its subsequent transport to the liver for further metabolism and biliary excretion. We have previously demonstrated in cultured hepatocytes that P2Y(13) (purinergic receptor P2Y, G protein-coupled, 13) activation is essential for HDL uptake but the potential of P2Y(13) as a target to promote RCT has not been documented. Here, we show that P2Y(13)-deficient mice exhibited a decrease in hepatic HDL cholesterol uptake, hepatic cholesterol content, and biliary cholesterol output, although their plasma HDL and other lipid levels were normal. These changes translated into a substantial decrease in the rate of macrophage-to-feces RCT. Therefore, hallmark features of RCT are impaired in P2Y(13)-deficient mice. Furthermore, cangrelor, a partial agonist of P2Y(13), stimulated hepatic HDL uptake and biliary lipid secretions in normal mice and in mice with a targeted deletion of scavenger receptor class B type I (SR-BI) in liver (hypomSR-BI-knockout(liver)) but had no effect in P2Y(13) knockout mice, which indicate that P2Y(13)-mediated HDL uptake pathway is independent of SR-BI-mediated HDL selective cholesteryl ester uptake. CONCLUSION These results establish P2Y(13) as an attractive novel target for modulating RCT and support the emerging view that steady-state plasma HDL levels do not necessarily reflect the capacity of HDL to promote RCT.
Collapse
Affiliation(s)
- Aurélie C Fabre
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 563, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Vanderstocken G, Bondue B, Horckmans M, Di Pietrantonio L, Robaye B, Boeynaems JM, Communi D. P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation. J Immunol 2010; 185:3702-7. [PMID: 20720203 DOI: 10.4049/jimmunol.0903908] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
ATP has been defined as a key mediator of asthma. In this study, we evaluated lung inflammation in mice deficient for the P2Y(2) purinergic receptor. We observed that eosinophil accumulation, a distinctive feature of lung allergic inflammation, was defective in OVA-treated P2Y(2)-deficient mice compared with OVA-treated wild type animals. Interestingly, the upregulation of VCAM-1 was lower on lung endothelial cells of OVA-treated P2Y(2)(-/-) mice compared with OVA-treated wild type animals. Adhesion assays demonstrated that the action of UTP on leukocyte adhesion through the regulation of endothelial VCAM-1 was abolished in P2Y(2)-deficient lung endothelial cells. Additionally, the level of soluble VCAM-1, reported as an inducer of eosinophil chemotaxis, was strongly reduced in the bronchoalveolar lavage fluid (BALF) of P2Y(2)-deficient mice. In contrast, we observed comparable infiltration of macrophages and neutrophils in the BALF of LPS-aerosolized P2Y(2)(+/+) and P2Y(2)(-/-) mice. This difference could be related to the much lower level of ATP in the BALF of LPS-treated mice compared with OVA-treated mice. Our data define P2Y(2) as a regulator of membrane and soluble forms of VCAM-1 and eosinophil accumulation during lung inflammation.
Collapse
Affiliation(s)
- Gilles Vanderstocken
- Institute of Interdisciplinary Research, Erasme Hospital, Free University of Brussels, Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
34
|
Cicko S, Lucattelli M, Müller T, Lommatzsch M, De Cunto G, Cardini S, Sundas W, Grimm M, Zeiser R, Dürk T, Zissel G, Boeynaems JM, Sorichter S, Ferrari D, Di Virgilio F, Virchow JC, Lungarella G, Idzko M. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol 2010; 185:688-97. [PMID: 20519655 DOI: 10.4049/jimmunol.0904042] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Extracellular ATP acts as a "danger signal" and can induce inflammation by binding to purinergic receptors. Chronic obstructive pulmonary disease is one of the most common inflammatory diseases associated with cigarette smoke inhalation, but the underlying mechanisms are incompletely understood. In this study, we show that endogenous pulmonary ATP levels are increased in a mouse model of smoke-induced acute lung inflammation and emphysema. ATP neutralization or nonspecific P2R-blockade markedly reduced smoke-induced lung inflammation and emphysema. We detected an upregulation the purinergic receptors subtypes on neutrophils (e.g., P2Y2R), macrophages, and lung tissue from animals with smoke-induced lung inflammation. By using P2Y(2)R deficient ((-/-)) animals, we show that ATP induces the recruitment of blood neutrophils to the lungs via P2Y(2)R. Moreover, P2Y(2)R deficient animals had a reduced pulmonary inflammation following acute smoke-exposure. A series of experiments with P2Y(2)R(-/-) and wild type chimera animals revealed that P2Y(2)R expression on hematopoietic cell plays the pivotal role in the observed effect. We demonstrate, for the first time, that endogenous ATP contributes to smoke-induced lung inflammation and then development of emphysema via activation of the purinergic receptor subtypes, such as P2Y(2)R.
Collapse
Affiliation(s)
- Sanja Cicko
- Department of Pulmonary Medicine, University Hospital, Freiburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Leroy K, Ando K, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buée L, De Decker R, Brion JP. Lithium Treatment Arrests the Development of Neurofibrillary Tangles in Mutant Tau Transgenic Mice with Advanced Neurofibrillary Pathology. ACTA ACUST UNITED AC 2010; 19:705-19. [DOI: 10.3233/jad-2010-1276] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Karelle Leroy
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Kunie Ando
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Céline Héraud
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Zehra Yilmaz
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Michèle Authelet
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-Marie Boeynaems
- Laboratory of Medical Biology, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Robert De Decker
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-Pierre Brion
- Laboratory of Histology, Neuroanatomy and Neuropathology, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| |
Collapse
|
36
|
Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer HD, Communi D, Boeynaems JM, Hausmann R, Schmalzing G, Kassack MU. NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther 2009; 332:238-47. [PMID: 19815812 DOI: 10.1124/jpet.109.157750] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The G protein-coupled P2Y(11) receptor is involved in immune system modulation. In-depth physiological evaluation is hampered, however, by a lack of selective and potent ligands. By screening a library of sulfonic and phosphonic acid derivatives at P2Y(11) receptors recombinantly expressed in human 1321N1 astrocytoma cells (calcium and cAMP assays), the selective non-nucleotide P2Y(11) agonist NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] was identified. NF546 had a pEC(50) of 6.27 and is relatively selective for P2Y(11) over P2Y(1), P2Y(2), P2Y(4), P2Y(6), P2Y(12), P2X(1), P2X(2), and P2X(2)-X(3). Adenosine-5'-O-(3-thio)triphosphate (ATPgammaS), a nonhydrolyzable analog of the physiological P2Y(11) agonist ATP, and NF546 use a common binding site as suggested by molecular modeling studies and their competitive behavior toward the nanomolar potency antagonist NF340 [4,4'-(carbonylbis(imino-3,1-(4-methyl-phenylene)carbonylimino))bis(naphthalene-2,6-disulfonic acid) tetrasodium salt] in Schild analysis. The pA(2) of NF340 was 8.02 against ATPgammaS and 8.04 against NF546 (calcium assays). NF546 was further tested for P2Y(11)-mediated effects in monocyte-derived dendritic cells. Similarly to ATPgammaS, NF546 led to thrombospondin-1 secretion and inhibition of lipopolysaccharide-stimulated interleukin-12 release, whereas NF340 inhibited these effects. Further, for the first time, it was shown that ATPgammaS or NF546 stimulation promotes interleukin 8 (IL-8) release from dendritic cells, which could be inhibited by NF340. In conclusion, we have described the first selective, non-nucleotide agonist NF546 for P2Y(11) receptors in both recombinant and physiological expression systems and could show a P2Y(11)-stimulated IL-8 release, further supporting the immunomodulatory role of P2Y(11) receptors.
Collapse
Affiliation(s)
- Sabine Meis
- Institute of Pharmaceutical and Medicinal Chemistry, Pharmaceutical Biochemistry, Heinrich-Heine-University of Duesseldorf, Duesseldorf, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Boeynaems JM. [Reimbursement and rational prescription of laboratory tests]. Rev Med Brux 2009; 30:446-449. [PMID: 19899393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Following the important growth of the Belgian laboratory medicine budget in the eighties, the mechanisms of reimbursement by the social security system have become more and more complex in the last 20 years. The current system is a dual one, with a lump sum complemented by an amount per test. The rules differ for hospitalized and non-hospitalized patients. New recently launched measures ("reference amounts") intend to decrease the prescription of laboratory tests in hospitals, while others targeting non-hospital practice are being considered. Beside these purely financial initiatives targeting the laboratories, another approach involves fostering a rational prescription of tests according to the results of interventional trials or international guidelines consistent with evidence-based medicine. The recent report of the KCE on laboratory tests prescription by general practitioners is consistent with this strategy.
Collapse
Affiliation(s)
- J M Boeynaems
- Département de Biologie Clinique, Hôpital Erasme, Bruxelles.
| |
Collapse
|
38
|
Di Virgilio F, Boeynaems JM, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009; 9:507-13. [PMID: 19628431 DOI: 10.1016/j.coph.2009.06.021] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2009] [Accepted: 06/23/2009] [Indexed: 12/13/2022]
Abstract
Nucleotides are well known for being the universal currency of intracellular energy transactions, but over the past decade it has become clear that they are also ubiquitous extracellular messengers. In the immune system there is increasing awareness that nucleotides serve multiple roles as stimulants of lymphocyte proliferation, ROS generation, cytokine and chemokine secretion: in one word as pro-inflammatory mediators. However, although often neglected, extracellular nucleotides exert an additional more subtle function as negative modulators of immunity, or as immunodepressants. The more we understand the peculiar biochemical composition of the microenvironment generated at inflammatory sites, the more we appreciate how chronic exposure to low extracellular nucleotide levels affect immunity and inflammation. A deeper understanding of this complex network will no doubt help design more effective therapies for cancer and chronic inflammatory diseases.
Collapse
Affiliation(s)
- Francesco Di Virgilio
- Department of Experimental and Diagnostic Medicine, Section of General Pathology, University of Ferrara, Italy.
| | | | | |
Collapse
|
39
|
Relvas LJM, Bouffioux C, Marcet B, Communi D, Makhoul M, Horckmans M, Blero D, Bruyns C, Caspers L, Boeynaems JM, Willermain F. Extracellular nucleotides and interleukin-8 production by ARPE cells: potential role of danger signals in blood-retinal barrier activation. Invest Ophthalmol Vis Sci 2008; 50:1241-6. [PMID: 19029040 DOI: 10.1167/iovs.08-1902] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE RPE cell activation is an important feature of autoimmune uveitis. This investigation focused on whether extracellular nucleotides could contribute to this activation, and the effects of ATPgammaS, UTP, and UDP on the production of IL-8 by RPE cells was studied in relation to their expression of functional P2Y receptors. METHODS ARPE-19 cells were cultured with ATPgammaS, UTP, UDP, and TNF. IL-8 gene transcription and protein production were measured by semiquantitative RT-PCR and ELISA. Western blot analysis and RT-PCR were used to investigate ERK 1/2 activation and P2Y expression. Changes in intracellular calcium and cAMP concentration were analyzed by spectrofluorometry and radioimmunoassay. RESULTS Stimulation of ARPE-19 cells with ATPgammaS, UTP, and UDP induced IL-8 gene transcription and protein secretion. TNFalpha induction of IL-8 secretion was also increased by ATPgammaS, UTP, and UDP. Nucleotide induction of IL-8 production was blocked by PD98059, and all nucleotides stimulated ERK 1/2 phosphorylation. P2Y(2) and P2Y(6) mRNAs were detected in ARPE-19 cells. All tested nucleotides induced a pulse of intracellular calcium. CONCLUSIONS ATPgammaS, UTP, and UDP stimulate both basal and TNFalpha-induced IL-8 secretion in RPE cells through an ERK 1/2-dependent pathway. The results suggest that those effects are mediated by P2Y(2) and P2Y(6) receptors.
Collapse
Affiliation(s)
- Lia Judice M Relvas
- Department of Ophthalmology, CHU Centre Hospitalier, Universitaire St-Pierre and Brugmann, Université Libre de Bruxelles-Campus Erasme, Bruxelles, Belgium
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ben Addi A, Lefort A, Hua X, Libert F, Communi D, Ledent C, Macours P, Tilley SL, Boeynaems JM, Robaye B. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol 2008; 38:1610-20. [PMID: 18465770 DOI: 10.1002/eji.200737781] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Adenosine triphosphate has previously been shown to induce semi-mature human monocyte-derived dendritic cells (DC). These are characterized by the up-regulation of co-stimulatory molecules, the inhibition of IL-12 and the up-regulation of some genes involved in immune tolerance, such as thrombospondin-1 and indoleamine 2,3-dioxygenase. The actions of adenosine triphosphate are mediated by the P2Y(11) receptor; since there is no functional P2Y(11) gene in the murine genome, we investigated the action of adenine nucleotides on murine DC. Adenosine 5'-(3-thiotriphosphate) and adenosine inhibited the production of IL-12p70 by bone marrow-derived DC (BMDC). These inhibitions were relieved by 8-p-sulfophenyltheophylline, an adenosine receptor antagonist. The use of selective ligands and A(2B) (-/-) BMDC indicated the involvement of the A(2B) receptor. A microarray experiment, confirmed by quantitative PCR, showed that, in presence of LPS, 5'-(N-ethylcarboxamido) adenosine (NECA, the most potent A(2B) receptor agonist) regulated the expression of several genes: arginase I and II, thrombospondin-1 and vascular endothelial growth factor were up-regulated whereas CCL2 and CCL12 were down-regulated. We further showed that NECA, in combination with LPS, increased the arginase I enzymatic activity. In conclusion, the described actions of adenine nucleotides on BMDC are mediated by their degradation product, adenosine, acting on the A(2B) receptor, and will possibly lead to an impairment of Th1 response or tolerance.
Collapse
Affiliation(s)
- Abduelhakem Ben Addi
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Macours P, Aubry JC, Hauquier B, Boeynaems JM, Goldman S, Moreno-Reyes R. Determination of urinary iodine by inductively coupled plasma mass spectrometry. J Trace Elem Med Biol 2008; 22:162-5. [PMID: 18565428 DOI: 10.1016/j.jtemb.2008.02.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 02/15/2008] [Accepted: 02/15/2008] [Indexed: 10/22/2022]
Abstract
BACKGROUND Mild iodine deficiency is endemic in many countries of Europe including Belgium. Fast, accurate and specific methods for quantification of urinary iodine are needed. We describe in this report a specific ICP-MS method for the quantification of urinary iodine. METHOD Samples and iodate calibrators were diluted 20 times into aqueous solution containing triton X-100, 1.5% HCl and (103)Rh as an internal standard. Prior digestion or oxidation was not necessary. Results were compared with those obtained by Sandell-Kolthoff (S-K) spectrophotometric method. RESULTS Comparison of both methods showed good agreement. The Passing-Bablok regression between both methods was ICP-MS=0.986 (S-K)-7.51. The Bland-Altman difference plot showed a small but significant mean difference of -13.3 microg/L for ICP-MS. The between-day coefficient of variation (CV) was 13% at 89 microg/L. Limit of detection was 4 microg/L and limit of quantification was 20 microg/L. No carryover effect has been observed on series containing up to 50 samples. CONCLUSION The ICP-MS method described here is fast, accurate and specific for the quantification of urinary iodine. Compared to the S-K method the urinary iodine concentrations measured by the ICP-MS method were slightly, but significantly lower. Consequently, the results of studies using S-K method should be compared with caution with those using the ICP-MS method.
Collapse
Affiliation(s)
- P Macours
- Laboratory of Clinical Chemistry, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Bruxelles, Belgium
| | | | | | | | | | | |
Collapse
|
42
|
Bles N, Horckmans M, Lefort A, Libert F, Macours P, El Housni H, Marteau F, Boeynaems JM, Communi D. Gene expression profiling defines ATP as a key regulator of human dendritic cell functions. J Immunol 2007; 179:3550-8. [PMID: 17785789 DOI: 10.4049/jimmunol.179.6.3550] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Extracellular ATP and PGE2 are two cAMP-elevating agents inducing semimaturation of human monocyte-derived dendritic cells (MoDCs). We have extensively compared the gene expression profiles induced by adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS) and PGE2 in human MoDCs using microarray technology. At 6 h of stimulation, ATPgammaS initiated an impressive expression profile compared with that of PGE2 (1125 genes compared with 133 genes, respectively) but after 24 h the number of genes regulated by ATPgammaS or PGE2 was more comparable. Many target genes involved in inflammation have been identified and validated by quantitative RT-PCR experiments. We have then focused on novel ATPgammaS and PGE2 target genes in MoDCs including CSF-1, MCP-4/CCL13 chemokine, vascular endothelial growth factor-A, and neuropilin-1. ATPgammaS strongly down-regulated CSF-1 receptor mRNA and CSF-1 secretion, which are involved in monocyte and dendritic cell (DC) differentiation. Additionally, ATPgammaS down-regulated several chemokines involved in monocyte and DC migration including CCL2/MCP-1, CCL3/MIP-1alpha, CCL4/MIP-1beta, CCL8/MCP-2, and CCL13/MCP-4. Interestingly, vascular endothelial growth factor A, a major angiogenic factor displaying immunosuppressive properties, was secreted by MoDCs in response to ATPgammaS, ATP, or PGE2, alone or in synergy with LPS. Finally, flow cytometry experiments have demonstrated that ATPgammaS, ATP, and PGE2 down-regulate neuropilin-1, a receptor playing inter alia an important role in the activation of T lymphocytes by DCs. Our data give an extensive overview of the genes regulated by ATPgammaS and PGE2 in MoDCs and an important insight into the therapeutic potential of ATP- and PGE2-treated human DCs.
Collapse
Affiliation(s)
- Nathalie Bles
- Institute of Interdisciplinary Research, Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Boeynaems JM, Communi D, Pirotton S, Motte S, Parmentier M. Involvement of distinct receptors in the actions of extracellular uridine nucleotides. Ciba Found Symp 2007; 198:266-74; discussion 274-7. [PMID: 8879830 DOI: 10.1002/9780470514900.ch15] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The P2 purinoceptors were initially defined as a family of receptors responsive to extracellular adenine nucleotides. In the late 1980s, it became clear that extracellular uridine nucleotides are also able to modulate cell function. The existence of a nucleotide receptor, common to ATP and UTP, was suggested by indirect pharmacological arguments (for instance the lack of additivity and the cross-desensitization of the responses to the two nucleotides) and later demonstrated by the cloning of a P2U receptor equally responsive to ATP and UTP. Vascular endothelial cells are a paradigm of cells on which both ATP and UTP exert physiologically relevant effects (stimulation of prostacyclin and nitric oxide release). Their response to nucleotides is mediated by two distinct receptors, both coupled to phospholipase C: a specific purinoceptor responsive to ATP and ADP (P2Y) and a nucleotide receptor responsive to ATP and UTP (P2U). We have recently cloned from the human genome a new subtype of receptor (tentatively called P2Y4), which is structurally related to the P2U receptor. Functional expression revealed its coupling to phospholipase C and its selective responsiveness to UTP and UDP. According to the new nomenclature, the P2 receptors that are coupled to G proteins belong to the P2Y family. It now appears that this family encompasses specific purinoceptors (P2Y1, formerly called P2Y), nucleotide receptors common to ATP and UTP (P2Y2, previously P2U) and selective pyrimidinoceptors (P2Y4). The existence of these pyrimidinoceptors suggests that uridine nucleotides may play a role as intercellular mediators, independently from adenine nucleotides.
Collapse
Affiliation(s)
- J M Boeynaems
- Institute of Interdisciplinary Research, School of Medicine, Université Libre de Bruxelles, Campus Hôpital Erasme, Belgium
| | | | | | | | | |
Collapse
|
44
|
Marcet B, Horckmans M, Libert F, Hassid S, Boeynaems JM, Communi D. Extracellular nucleotides regulate CCL20 release from human primary airway epithelial cells, monocytes and monocyte-derived dendritic cells. J Cell Physiol 2007; 211:716-27. [PMID: 17295217 DOI: 10.1002/jcp.20979] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Extracellular nucleotides regulate ion transport and mucociliary clearance in human airway epithelial cells (HAECs) via the activation of P2 receptors, especially P2Y(2). Therefore, P2Y(2) receptor agonists represent potential pharmacotherapeutic agents to treat cystic fibrosis (CF). Nucleotides also modulate inflammatory properties of immune cells like dendritic cells (DCs), which play an important role in mucosal immunity. Using DNA-microarray experiments, quantitative RT-PCR and cytokine measurements, we show here that UTP up-regulated approximately 2- to 3-fold the antimicrobial chemokine CCL20 expression and release in primary HAECs cultured on permeable supports at an air-liquid interface (ALI). Both P2Y(2) (ATPgammaS, UTP, INS365) and P2Y(6) (UDP, INS48823) agonists increased CCL20 release. UTP-induced CCL20 release was insensitive to NF-kappaB pathway inhibitors but sensitive to inhibitors of ERK1/2 and p38/MAPK pathways. Furthermore, UTP had no effect on interleukin-(IL)-8 release and reduced the release of both CCL20 and IL-8 induced by TNF-alpha and LPS. Accordingly, UTP reduced the capacity of basolateral supernatants of HAECs treated with TNF-alpha or LPS to induce the chemoattraction of both CD4(+) T lymphocytes and neutrophils. In addition, we show that, in monocyte-derived DCs, ATPgammaS, and UDP but not UTP/INS365-stimulated CCL20 release. Likewise, UDP but not ATPgammaS was also able to increase CCL20 release from monocytes. Pharmacological experiments suggested an involvement of P2Y(11) or P2Y(6) receptors through NF-kappaB, ERK1/2, and p38/MAPK pathways. Altogether, our data demonstrate that nucleotides may modulate chemokine release and leukocyte recruitment in inflamed airways by acting on both epithelial and immune cells. Our results could be relevant for further clinical investigations in CF.
Collapse
Affiliation(s)
- Brice Marcet
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Brussels, Belgium.
| | | | | | | | | | | |
Collapse
|
45
|
Marcet B, Libert F, Boeynaems JM, Communi D. Extracellular nucleotides induce COX-2 up-regulation and prostaglandin E2 production in human A549 alveolar type II epithelial cells. Eur J Pharmacol 2007; 566:167-71. [PMID: 17481603 DOI: 10.1016/j.ejphar.2007.04.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2007] [Revised: 03/27/2007] [Accepted: 04/01/2007] [Indexed: 11/19/2022]
Abstract
Extracellular nucleotides regulate ion transport, mucociliary clearance as well as inflammatory properties of the airway epithelium by acting on P2 receptors. Cyclooxygenase-2 (COX-2) is a key enzyme involved in the synthesis of prostaglandins during inflammation. In this study, using calcium imaging, DNA microarray experiments, real-time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) and prostaglandin E2 (PGE2) measurement, we show for the first time that ATP, UTP or INS365 compound (P2Y2 receptor agonists) up-regulate COX-2 expression by approximately 3-fold and enhance the release of PGE2 in human A549 airway epithelial cells. Our data suggest that P2Y receptors may represent putative targets in airway inflammatory diseases.
Collapse
Affiliation(s)
- Brice Marcet
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, and Department of Medical Chemistry, Erasme Hospital, Brussels, Belgium.
| | | | | | | |
Collapse
|
46
|
Matos JE, Sorensen MV, Geyti CS, Robaye B, Boeynaems JM, Leipziger J. Distal colonic Na(+) absorption inhibited by luminal P2Y(2) receptors. Pflugers Arch 2007; 454:977-87. [PMID: 17356885 DOI: 10.1007/s00424-007-0248-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2007] [Accepted: 02/28/2007] [Indexed: 10/23/2022]
Abstract
Luminal P2 receptors are ubiquitously expressed in transporting epithelia. In steroid-sensitive epithelia (e.g., lung, distal nephron) epithelial Na(+) channel (ENaC)-mediated Na(+) absorption is inhibited via luminal P2 receptors. In distal mouse colon, we have identified that both, a luminal P2Y(2) and a luminal P2Y(4) receptor, stimulate K(+) secretion. In this study, we investigate the effect of luminal adenosine triphosphate/uridine triphosphate (ATP/UTP) on electrogenic Na(+) absorption in distal colonic mucosa of mice treated on a low Na(+) diet for more than 2 weeks. Transepithelial electrical parameters were recorded in an Ussing chamber. Baseline parameters: transepithelial voltage (V (te)): -13.7 +/- 1.9 mV (lumen negative), transepithelial resistance (R (te)): 24.1 +/- 1.8 Omega cm(2), equivalent short circuit current (I (sc)): -563.9 +/- 63.8 microA/cm(2) (n = 21). Amiloride completely inhibited I (sc) to -0.5 +/- 8.5 microA/cm(2). Luminal ATP induced a slowly on-setting and persistent inhibition of the amiloride-sensitive I (sc) by 160.7 +/- 29.7 microA/cm(2) (n = 12, NMRI mice). Luminal ATP and UTP were almost equipotent with IC(50) values of 10 microM and 3 microM respectively. In P2Y(2) knock-out (KO) mice, the effect of luminal UTP on amiloride-sensitve Na(+) absorption was absent. In contrast, in P2Y(4) KO mice the inhibitory effect of luminal UTP on Na(+) absorption remained present. Semiquantitative polymerase chain reaction did not indicate regulation of the P2Y receptors under low Na(+) diet, but it revealed a pronounced axial expression of both receptors with highest abundance in surface epithelia. Thus, luminal P2Y(2) and P2Y(4) receptors and ENaC channels co-localize in surface epithelium. Intriguingly, only the stimulation of the P2Y(2) receptor mediates inhibition of electrogenic Na(+) absorption.
Collapse
Affiliation(s)
- J E Matos
- Institute of Physiology and Biophysics, The Water and Salt Research Center, University of Aarhus, Aarhus, Denmark
| | | | | | | | | | | |
Collapse
|
47
|
Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006; 58:281-341. [PMID: 16968944 PMCID: PMC3471216 DOI: 10.1124/pr.58.3.3] [Citation(s) in RCA: 974] [Impact Index Per Article: 54.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
There have been many advances in our knowledge about different aspects of P2Y receptor signaling since the last review published by our International Union of Pharmacology subcommittee. More receptor subtypes have been cloned and characterized and most orphan receptors de-orphanized, so that it is now possible to provide a basis for a future subdivision of P2Y receptor subtypes. More is known about the functional elements of the P2Y receptor molecules and the signaling pathways involved, including interactions with ion channels. There have been substantial developments in the design of selective agonists and antagonists to some of the P2Y receptor subtypes. There are new findings about the mechanisms underlying nucleotide release and ectoenzymatic nucleotide breakdown. Interactions between P2Y receptors and receptors to other signaling molecules have been explored as well as P2Y-mediated control of gene transcription. The distribution and roles of P2Y receptor subtypes in many different cell types are better understood and P2Y receptor-related compounds are being explored for therapeutic purposes. These and other advances are discussed in the present review.
Collapse
Affiliation(s)
- Maria P Abbracchio
- Department of Pharmacological Sciences, University of Milan, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Marcet B, Boeynaems JM. Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis. Pharmacol Ther 2006; 112:719-32. [PMID: 16828872 DOI: 10.1016/j.pharmthera.2006.05.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2006] [Accepted: 05/26/2006] [Indexed: 10/24/2022]
Abstract
Cystic fibrosis (CF) is one of the most common lethal autosomal recessive genetic diseases in the Caucasian population, with a frequency of about 1 in 3000 livebirths. CF is due to a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding the CFTR protein, a cyclic adenosine 5'-monophosphate (cAMP)-regulated chloride channel localized in the apical membrane of epithelial cells. CFTR is a multifunctional protein which, in addition to be a Cl-channel, is also a regulator of multiple ion channels and other proteins. In particular CFTR has been reported to play a role in the outflow of adenosine 5'-triphosphate (ATP) from cells, but this remains controversial. Extracellular nucleotides are signaling molecules that regulate ion transport and mucociliary clearance by acting on P2 nucleotide receptors, in particular the P2Y(2) receptor. Nucleotides activating the P2Y(2) receptor represent thus one pharmacotherapeutic strategy to treat CF disease, via improvement of mucus hydration and mucociliary clearance in airways. Phase II clinical trials have recently shown that aerosolized denufosol (INS37217, Inspire(R)) improves pulmonary function in CF patients: denufosol was granted orphan drug status and phase III trials are planned. Here, we review what is known about the relationship between extracellular nucleotides and CFTR, the role of extracellular nucleotides in epithelial pathophysiology and their putative role as therapeutic agents.
Collapse
Affiliation(s)
- Brice Marcet
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Campus Erasme (Bât C5-110), route de Lennik 808, 1070 Brussels, Belgium.
| | | |
Collapse
|
49
|
Abstract
In this issue, Seiffert et al. show that adenosine triphosphate enhances the production of inflammatory mediators by human dermal endothelial cells. However, a growing literature shows that adenosine triphosphate exerts anti-inflammatory effects, partly by inducing a semi-maturation of dendritic cells associated with immune tolerance. These discrepancies can be reconciled knowing that extracellular nucleotides constitute danger signals that are released in response to both external aggression (chemical, microbial) and excess inflammation.
Collapse
Affiliation(s)
- Jean-Marie Boeynaems
- Université Libre de Bruxelles, Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, and Laboratory of Medical Chemistry, Erasme Hospital, 808 Route de Lennik, 1070 Brussels, Belgium.
| | | |
Collapse
|
50
|
Guns PJDF, Van Assche T, Fransen P, Robaye B, Boeynaems JM, Bult H. Endothelium-dependent relaxation evoked by ATP and UTP in the aorta of P2Y2-deficient mice. Br J Pharmacol 2006; 147:569-74. [PMID: 16415908 PMCID: PMC1616985 DOI: 10.1038/sj.bjp.0706642] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Based on pharmacological criteria, we previously suggested that in the mouse aorta, endothelium-dependent relaxation by nucleotides is mediated by P2Y1 (adenosine diphosphate (ADP)), P2Y2 (adenosine triphosphate (ATP)) and P2Y6 (uridine diphosphate (UDP)) receptors. For UTP, it was unclear whether P2Y2, P2Y6 or yet another subtype was involved. Therefore, in view of the lack of selective purinergic agonists and antagonists, we used P2Y2-deficient mice to clarify the action of UTP. Thoracic aorta segments (width 2 mm) of P2Y2-deficient and wild-type (WT) mice were mounted in organ baths to measure isometric force development and intracellular calcium signalling. Relaxations evoked by ADP, UDP and acetylcholine were identical in knockout and WT mice, indicating that the receptors for these agonists function normally. P2Y2-deficient mice showed impaired ATP- and adenosine 5'[gamma-thio] triphosphate (ATPgammaS)-evoked relaxation, suggesting that in WT mice, ATP and ATPgammaS activate predominantly the P2Y2 subtype. The ATP/ATPgammaS-evoked relaxation and calcium signals in the knockout mice were partially rescued by P2Y1, as they were sensitive to 2'-deoxy-N6-methyladenosine 3',5'-bisphosphate (MRS2179), a P2Y1-selective antagonist. In contrast to ATP, the UTP-evoked relaxation was not different between knockout and WT mice. Moreover, the action of UTP was not sensitive to MRS2179. Therefore, the action of UTP is probably mediated mainly by a P2Y6(like) receptor subtype. In conclusion, we demonstrated that ATP-evoked relaxation of the murine aorta is mainly mediated by P2Y2. But this P2Y2 receptor has apparently no major role in UTP-evoked relaxation. The vasodilator effect of UTP is probably mediated mainly by a P2Y6(like) receptor.
Collapse
Affiliation(s)
- Pieter-Jan D F Guns
- Division of Pharmacology, University of Antwerp, Universiteitsplein 1 (building T2), B-2610 Wilrijk, and Laboratory of Medical Chemistry, Erasme Hospital, Belgium.
| | | | | | | | | | | |
Collapse
|